Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $7.
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $7.